Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Sees Significant Growth in Short Interest

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totaling 5,039 shares, a growth of 68.9% from the September 30th total of 2,984 shares. Based on an average trading volume of 4,298 shares, the short-interest ratio is currently 1.2 days.

Insider Buying and Selling

In other Leverage Shares 2X Long FIX Daily ETF news, CEO Jodie Pope Morrison sold 3,221 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $8.32, for a total value of $26,798.72. Following the sale, the chief executive officer owned 340,038 shares in the company, valued at approximately $2,829,116.16. This represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $46,334.88. Following the transaction, the insider directly owned 127,771 shares of the company’s stock, valued at $2,115,887.76. This represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 22,054 shares of company stock valued at $320,397 over the last quarter.

Leverage Shares 2X Long FIX Daily ETF Price Performance

FIXX stock opened at $7.28 on Wednesday. The company’s 50 day moving average is $11.39. Leverage Shares 2X Long FIX Daily ETF has a twelve month low of $5.61 and a twelve month high of $15.92.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.